Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ipilimumab in Locally Advanced Malignant Neoplasm: NCT07751055 Clinical Landscape Report 2026
28 September 2026
NCT07751055 clinical landscape for Locally Advanced Malignant Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
SHR-9839 in Advanced Esophageal Squamous Cell Carcinoma: NCT07751341 Clinical Landscape Report 2026
28 September 2026
NCT07751341 clinical landscape for Advanced Esophageal Squamous Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
GLP-1 agonist (Nxera Pharma) in Arthritis: NCT07755085 Clinical Landscape Report 2026
28 September 2026
NCT07755085 clinical landscape for Arthritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Semaglutide (Novo Nordisk) in Obesity: ACTRN12626001033336 Clinical Landscape Report 2026
28 September 2026
ACTRN12626001033336 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CEL001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
CEL001: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Phenserine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Phenserine: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ABBV-553 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
ABBV-553: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
GO-4305 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
GO-4305: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
STRO-004 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
STRO-004: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
SUDO-550 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
SUDO-550: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
MGC-026 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
MGC-026: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
DEC003M Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
DEC003M: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.